Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...
an inflammatory condition that causes recurrent hives and swelling. That sets up the start of a phase 3 programme later this year for what the French drugmaker has called a “pipeline in a pill”.